Transdermal oestrogen for treatment of severe postnatal depression
- PMID: 8598756
- DOI: 10.1016/s0140-6736(96)91414-2
Transdermal oestrogen for treatment of severe postnatal depression
Abstract
Background: Postnatal depression can have long-term adverse consequences for the mother, for the marital relationship, and for the infant's psychological development. Such depressions can be severe and resistant to both support and counselling and to therapy with antidepressant drugs. We investigated the antidepressant efficacy of oestrogen given transdermally.
Methods: In a double-blind, placebo-controlled study, 61 women with major depression, which began within 3 months of childbirth and persisted for up to 18 months postnatally, were allocated randomly active treatment (n=34; 3 months of transdermal 17 beta-oestradiol 200 micrograms daily alone, then 3 months with added cyclical dydrogesterone 10mg daily for 12 days each month) or placebo (n=27; placebo patches and tablets according to the same regimen). The women were assessed monthly by self-ratings of depressive symptoms on the Edinburgh postnatal depression scale (EPDS) and by clinical psychiatric interview (schedule for affective disorders and schizophrenia [SADS]-change scale).
Findings: On pretreatment assessments the women in both groups were severely depressed (mean EPDS score 21.8 [SD 3.0] active group, 21.3 [2.9] placebo group; SADS scores, 66.3 [11.4] and 64.3 [10.7]). During the first month of therapy the women receiving oestrogen improved rapidly, and to a significantly greater extent than controls (mean EPDS scores 13.3 [SD 5.7] vs 16.5 [5.3]. Patients receiving placebo also improved over time but, on average, their scores did not fall below the screening threshold for major depression for at least 4 months. The estimated overall treatment effect of oestrogen on the EPDS was 4.38 points (95% Cl 1.89-6.87). None of a range of other factors (age, psychiatric, obstetric and gynaecological history, severity and duration of current episode of depression, and concurrent antidepressant medication), influenced the response to oestrogen.
Interpretation: This study has shown that transdermal oestrogen is an effective treatment for postnatal depression. Further studies are required to establish the minimum effective dose and shortest necessary duration of treatment as well as the mechanism of antidepressant action of oestrogen.
Comment in
-
Oestrogen and postnatal depression.Lancet. 1996 Apr 6;347(9006):918-9. doi: 10.1016/s0140-6736(96)91409-9. Lancet. 1996. PMID: 8598751 No abstract available.
Similar articles
-
Novel Augmentation Strategies in Major Depression.Dan Med J. 2017 Apr;64(4):B5338. Dan Med J. 2017. PMID: 28385173 Review.
-
Transdermal estradiol for postpartum depression: results from a pilot randomized, double-blind, placebo-controlled study.Arch Womens Ment Health. 2020 Jun;23(3):401-412. doi: 10.1007/s00737-019-00991-3. Epub 2019 Aug 1. Arch Womens Ment Health. 2020. PMID: 31372757 Free PMC article. Clinical Trial.
-
[Screening and intervention for depressive mothers of new-born infants].Seishin Shinkeigaku Zasshi. 2003;105(9):1129-35. Seishin Shinkeigaku Zasshi. 2003. PMID: 14639935 Japanese.
-
Improvement in depression with oestrogen treatment in women with schizophrenia.Arch Womens Ment Health. 2020 Apr;23(2):149-154. doi: 10.1007/s00737-019-00959-3. Epub 2019 Mar 21. Arch Womens Ment Health. 2020. PMID: 30903287 Clinical Trial.
-
The benefit of oestrogens and progestogens in postnatal depression.J Obstet Gynaecol. 2003 Jul;23(4):341-6. doi: 10.1080/0144361031000119448. J Obstet Gynaecol. 2003. PMID: 12881067 Review.
Cited by
-
The role of gut microbiota and blood metabolites in postpartum depression: a Mendelian randomization analysis.Front Cell Infect Microbiol. 2024 Jul 10;14:1416298. doi: 10.3389/fcimb.2024.1416298. eCollection 2024. Front Cell Infect Microbiol. 2024. PMID: 39050131 Free PMC article.
-
Prolonged HPA axis dysregulation in postpartum depression associated with adverse early life experiences: A cross-species translational study.Nat Ment Health. 2024 May;2(5):593-604. doi: 10.1038/s44220-024-00217-1. Epub 2024 Apr 11. Nat Ment Health. 2024. PMID: 38736646 Free PMC article.
-
Depression in Women: Potential Biological and Sociocultural Factors Driving the Sex Effect.Neuropsychobiology. 2024;83(1):2-16. doi: 10.1159/000531588. Epub 2024 Jan 25. Neuropsychobiology. 2024. PMID: 38272005 Free PMC article. Review.
-
Current pharmacotherapy approaches and novel GABAergic antidepressant development in postpartum depression.Dialogues Clin Neurosci. 2023 Dec;25(1):92-100. doi: 10.1080/19585969.2023.2262464. Epub 2023 Oct 5. Dialogues Clin Neurosci. 2023. PMID: 37796239 Free PMC article. Review.
-
Post-partum depression: From clinical understanding to preclinical assessments.Front Psychiatry. 2023 Apr 18;14:1173635. doi: 10.3389/fpsyt.2023.1173635. eCollection 2023. Front Psychiatry. 2023. PMID: 37143780 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical